Evaluating Mental Health Improvements After Using Home Phototherapy Device With UVB LEDs

Light House- Pilot Study Evaluating Mental Health Improvements After Using Home Phototherapy Device With UVB LEDs

The primary objective of this study is to evaluate the satisfaction of users with the MySOLIUS device by a non-professional in a home use environment. The secondary objective of this study is to demonstrate the safety and effectiveness of the MySOLIUS device in the improvement of mood/quality of life score.

Study Overview

• Status: Completed
• Conditions: Quality of Life; Usability
• Intervention / Treatment: Device: MySOLIUS

Detailed Description

After being informed about the study and potential risks, all patients giving written informed consent will be screened to determine eligibility for study entry. Participants who meet the eligibility requirements will be sent a study device to use in their home environment. Prior to beginning treatment with the device, participants will fill out a quality of life questionnaire. Participants will use the device twice per week, once for treatment on the front side and once for treatment on the back side of the body. Participants will use the device twice a week for 16 weeks, for a total of 32 treatments. After the 16 week treatment duration, participants will fill out a final quality of life questionnaire and a device usability questionnaire.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • British Colimbia
    • Surrey, British Colimbia, Canada, V3R 6A7
      • Dr. Chih-Ho Hong Medical Inc.
• United States
  • California
    • Irvine, California, United States, 92620
      • Office of Jashin J. Wu, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Men and women, age 18 years or older with Fitzpatrick skin types 1,2,3,4,5 and 6.
• The patient can understand the information provided to them and who have given written informed consent to the study.
• The patient can understand and complete self-administered questionnaires.
• The patient is able and willing to follow study procedures.
• Women of child-bearing potential must confirm use of an effective contraceptive for 30 days prior to enrolling and continued use throughout the study or have a negative pregnancy test.

Exclusion Criteria:

• History of underlying photosensitivity.
• Subjects who are pregnant
• Patients that have granulomatous disorders (such as sarcoidosis).
• Use of medications that cause a photosensitivity reaction.
• History of skin cancer in the last 5 years.
• Patients with history of hypocalcemia (calcium <8.6mg%), hypercalcemia(calcium >10.6mg%).
• Taking drugs known to influence vitamin D metabolism, such as glucocorticoids,antiseizure medications, or HIV/AIDS medications.
• Patients with a history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease within 3 months.
• Intentional artificial UV exposure (e.g. tanning bed, UVB phototherapy use) in the last 60 days or planned use while participating in the study.
• Participation in an investigational drug study within 30 days of the screening.
• Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Device Feasibility
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Device user; Participant will engage in treatment with the MySOLIUS device, twice per week for 16 weeks	Device: MySOLIUS; MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Satisfaction of Users with the device by a non-professional in a home use environment.	Participants will be surveyed on their satisfaction with the MySOLIUS device on a scale of Strongly Disagree (1) to Strongly Agree (7)	After study completion, 16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Increase in the quality of life scale.	Participants will be surveyed on a variety of quality of life questions. Scores range from a minimum value of 0 to a maximum value of 1,300 with higher scores indicating a better quality of life.	Prior to starting treatment and after study completion, 16 weeks
Composite of adverse events and any skin changes	Participants will be asked weekly if they experience any adverse events or skin changes.	16 weeks

Collaborators and Investigators

• Sponsor: BeneSol, Inc. dba SOLIUS

Study record dates

Study Major Dates

• Study Start (Actual): October 12, 2021
• Primary Completion (Actual): April 12, 2023
• Study Completion (Actual): April 12, 2023

Study Registration Dates

• First Submitted: January 17, 2022
• First Submitted That Met QC Criteria: February 1, 2022
• First Posted (Actual): February 11, 2022

Study Record Updates

• Last Update Posted (Actual): April 25, 2023
• Last Update Submitted That Met QC Criteria: April 24, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: QR-TPL-042

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data will not be made available to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes